{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:13:29Z","timestamp":1777511609897,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>To evaluate the efficacy and tolerability of quetiapine for the treatment of generalized anxiety disorder (<jats:styled-content style=\"fixed-case\">GAD)<\/jats:styled-content>, a literature search of the Medline database was conducted from inception to May 2014. The search was not restricted by language. Keywords used in the search were <jats:italic>quetiapine<\/jats:italic> and <jats:italic>generalized anxiety disorder<\/jats:italic> or <jats:italic>anxiety<\/jats:italic>. All studies assessing the use of quetiapine as monotherapy or adjunct therapy for the primary management of <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content> in adults 18\u201365\u00a0years of age were included in this review. The nine studies included in this review were three studies evaluating the use of quetiapine extended release (<jats:styled-content style=\"fixed-case\">XR)<\/jats:styled-content> as monotherapy for acute <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content> treatment, one study evaluating quetiapine <jats:styled-content style=\"fixed-case\">XR<\/jats:styled-content> monotherapy for maintenance treatment of <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content>, and five studies evaluating quetiapine (2 <jats:styled-content style=\"fixed-case\">XR<\/jats:styled-content>, 3 immediate release) as adjunct therapy for acute <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content> treatment. Quetiapine displayed both efficacy and tolerability in all monotherapy trials evaluating its use for acute and long\u2010term treatment of <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content>. Despite some limitations to and heterogeneity among the five adjunct therapy studies, three studies showed that quetiapine resulted in statistically significant changes in the Hamilton Anxiety Rating Scale or Clinical Global Impressions\u2010Severity of Illness Scale scores. Although future studies of longer duration with broader inclusion criteria are needed to further evaluate the benefits and risks of quetiapine for <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content>, in patients failing to respond to conventional antidepressant therapy, quetiapine may be a potential treatment option. With appropriate monitoring and management of adverse effects, the potential benefits of quetiapine in patients with treatment\u2010refractory <jats:styled-content style=\"fixed-case\">GAD<\/jats:styled-content> may outweigh the risks associated with its use.<\/jats:p>","DOI":"10.1002\/phar.1529","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T07:20:18Z","timestamp":1424157618000},"page":"175-188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Literature Review of Quetiapine for Generalized Anxiety Disorder"],"prefix":"10.1002","volume":"35","author":[{"given":"Tiffany\u2010Jade M.","family":"Kreys","sequence":"first","affiliation":[{"name":"California Northstate University College of Pharmacy Elk Grove California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie V.","family":"Phan","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy Southwest Georgia Clinical Campus Albany Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291705006069"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.s.7002.04"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20674"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1199"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"e_1_2_8_10_1","unstructured":"ScottM.Seroquel XR (quetiapine fumarate) for major depressive disorder (MDD) or generalized anxiety disorder (GAD).United States Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. April 9 2009. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM248418.pdf. Accessed December 12 2012."},{"key":"e_1_2_8_11_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research.Summary minutes for the Psychopharmacologic Drugs Advisory Committee.http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM198219.pdf. Accessed December 12 2012."},{"key":"e_1_2_8_12_1","unstructured":"Seroquel and Seroquel XR (quetiapine fumarate) pediatric post\u2010marketing drug utilization review. December2011."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283430a0e"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S3238"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301646"},{"key":"e_1_2_8_16_1","volume-title":"Buspar [buspirone hydrochloride]: prescribing information","year":"2010"},{"key":"e_1_2_8_17_1","volume-title":"Seroquel (quetiapine tablets): US prescribing information","year":"2013"},{"key":"e_1_2_8_18_1","volume-title":"Seroquel XR (quetiapine extended\u2010release tablets): US prescribing information","year":"2013"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.09.026"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f2d42c"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0420f"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990423"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318224864d"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834d9f49"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833e34d9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2008.03.002"},{"key":"e_1_2_8_27_1","first-page":"113","article-title":"The extended\u2010release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study","volume":"162","author":"Gabriel A","year":"2011","journal-title":"Clin Ter"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1087-x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283457d73"},{"key":"e_1_2_8_30_1","first-page":"E7","article-title":"Extended\u2010release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double\u2010blind study","volume":"25","author":"Khan A","year":"2013","journal-title":"Ann Clin Psychiatry"},{"issue":"19","key":"e_1_2_8_31_1","first-page":"20","article-title":"Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission","volume":"62","author":"Pollack MH","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1256"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505001110"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00003"},{"issue":"1","key":"e_1_2_8_35_1","first-page":"1","article-title":"Second\u2010generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09r05535gre"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571000101X"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20041"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1529","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:47:37Z","timestamp":1761054457000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1002\/phar.1529"],"URL":"https:\/\/doi.org\/10.1002\/phar.1529","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"2015-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}